Advanced Search
Users Online: 917
Home
About us
Editorial board
Ahead of print
Current issue
Search
Archives
Submit article
Instructions
Subscribe
Contacts
Reader Login
Export selected to
Endnote
Reference Manager
Procite
Medlars Format
RefWorks Format
BibTex Format
Access statistics : Table of Contents
2022| January-June | Volume 8 | Issue 1
Online since
June 11, 2022
Archives
Previous Issue
Next Issue
Most popular articles
Most cited articles
Show all abstracts
Show selected abstracts
Export selected to
Viewed
PDF
Cited
REVIEW ARTICLE
Oral minoxidil in trichology: A review
Priyanka Arun Kowe, Bhushan Madke, Shashank Hemant Bansod
January-June 2022, 8(1):1-6
DOI
:10.4103/ijdd.ijdd_35_21
Minoxidil, a pro-drug has been used as an oral antihypertensive drug since the 1960s. Though it was initially introduced as a therapy to control hypertension, it became popular after its coincidental finding on the promotion of hair growth and stimulation of new hair production. This has led to the usefulness of minoxidil in treating several hair loss disorders in both topical and oral forms. In 1988, Food and drug administration (FDA) approved topical minoxidil (TM) 2% for the treatment of male androgenetic alopecia (AGA) and in 1992, it got approval for female pattern hair loss (FPHL). Since then the use of TM has increased tremendously. However, there are frequent reports of TM and/or its vehicle-induced contact dermatitis which has reduced the compliance in the patients resulted in a poor outcome. Oral minoxidil (OM) has been tried and found useful in AGA, alopecia areata (AA), traction alopecia (TA), chronic telogen effluvium (CTE), chemotherapy-induced alopecia, monilethrix, and several other alopecia’s; however, the exact mechanism of action and efficacy of oral minoxidil in these disorders remains undetermined. Also, when given in low dose, side effect profile of OM has been found comparable to that of TM. The above data was supported by case series, randomized control trials, and case reports with a low quality of evidence. In this review, we aimed to summarize the different indications of oral minoxidil. We reiterate the claim that high-quality studies are needed before advocating use of oral minoxidil in hair disorders.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
8,310
268
-
BRIEF REPORT
A case series of generalized Lichenoid Drug Eruption due to Anti-Tubercular Drugs: Treated with immunosuppressant’s while continuing Anti-Tubercular therapy
Hari Pathave, Atul Dongre, Gayatri Gund, Sapna Goutham, Chitra Nayak
January-June 2022, 8(1):23-28
DOI
:10.4103/ijdd.ijdd_65_20
The spectrum of tuberculosis-associated cutaneous adverse drug reactions (ADRs) is wide and includes Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome and generalized lichenoid drug eruption (LDE). LDE constitutes less than 10% of the total incidence of anti-tubercular drug induced cutaneous ADRs. In any type of drug reaction there is a prompt need of withdrawal of suspected drugs and institution of aggressive treatment of ADRs with proper control of underlying primary disease. Herein, we present a case series of five cases of generalized LDE due to anti tubercular therapy (ATT), in whom cutaneous lesions were managed with oral immunosuppressants while continuing ATT.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
3,158
80
-
ORIGINAL ARTICLES
Serum and sebum pharmacokinetics evaluation of a novel formulation of itraconazole in healthy volunteers
Harshal Mahajan, Gaurav K Jain, Dhiraj Dhoot, Gaurav A Deshmukh, Hanmant V Barkate
January-June 2022, 8(1):7-14
DOI
:10.4103/ijdd.ijdd_23_21
Background and Objective:
Super bioavailable itraconazole is a newer formulation of itraconazole, which overcomes challenges encountered with the use of conventional itraconazole like interpatient variability, limited absorption, reduction in its absorption with co-administered gastric acid lowering agents, etc. The present study was done to evaluate the plasma pharmacokinetics, sebum concentrations of super bioavailable itraconazole in comparison with conventional itraconazole.
Materials and Methods:
Twelve healthy Asian Indian male healthy volunteers were enrolled in single-center, open-labeled, two treatments, multi-dose, parallel pharmacokinetic study. Test drug (T), i.e. super bioavailable itraconazole 50 mg, was given to six volunteers twice daily after meals for 7 continuous days. Reference drug (R), i.e. conventional itraconazole 100 mg, was given in similar way to the remaining six volunteers. Concentration of the itraconazole in plasma in both the groups was quantified by using high performance liquid chromatography. Concentration of the itraconazole in sebum was measured by paper absorption method.
Results:
The plasma concentration of itraconazole in both the groups was comparable at all-time points. The maximum concentration (C
max
) and area under curve in test group was higher as compared to reference group. The relative bioavailability of test drug was 107% as compared to the reference drug. The intersubject variability was less in test group (8.37%) as compared to reference drug (19.82%). At day 7, the mean sebum concentration of itraconazole in test drug group was 11.6% higher as compared to reference drug (
P
= 0.01).
Conclusion:
It is apparent from the study outcomes that super bioavailable itraconazole (50 mg) is bioequivalent to the conventional itraconazole (100 mg) along with less intersubject variability, and most importantly higher sebum concentration as compared to conventional itraconazole.
[ABSTRACT]
[FULL TEXT]
[PDF]
2,753
159
-
Dermatological adverse events of cancer chemotherapy: An observational clinicoepidemiological study from a tertiary care center
Guneet Awal, Guramrit Singh
January-June 2022, 8(1):15-22
DOI
:10.4103/ijdd.ijdd_36_21
Introduction:
Although newer chemotherapeutic drugs prolong patients’ survival, they cause a myriad of dermatological adverse effects leading to decreased quality of life.
Aims and Objectives:
The study was undertaken to assess the various cutaneous adverse effects associated with chemotherapeutic drugs.
Materials and Methods:
A total of 736 diagnosed cancer patients on chemotherapy attending the dermatology department of a tertiary care center were studied in this observational study between June 2019 and May 2021. Detailed dermatological examination to include skin, hair, nail, and mucosal changes was undertaken after informed consent.
Results:
The most common malignancy observed was breast carcinoma, which was seen in 21.33% of the cases. It was followed by carcinoma cervix in 12.09% of the cases. Most commonly implicated drugs were platinum therapy (cisplatin, carboplatin) and anthracyclines (doxorubicin and epirubicin). Alopecia was the most common adverse effect seen in 55.84% of the patients. It was followed by hand-foot syndrome in 11% of the patients. Nail changes were seen in 4.21% of the patients, and the most common nail finding was longitudinal melanonychia seen in 1.49% of the patients.
Conclusion:
Knowledge regarding occurrence and severity of dermatological side effects of chemotherapy aids in early recognition and treatment. It also benefits in educating patients regarding potential adverse effects, taking appropriate prophylactic measures, and therefore better compliance by the patient.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
2,543
105
-
CASE REPORTS
Pentoxifylline in the treatment of generalized granuloma annulare: A report of three cases
Vidya D Kharkar, Harish Balaji Rajendran, Anmol Bhargava
January-June 2022, 8(1):32-37
DOI
:10.4103/ijdd.ijdd_15_21
Granuloma annulare (GA) is a benign self-limited granulomatous cutaneous disorder of unknown etiology. Clinical variants include localized, generalized, perforating, and subcutaneous.
Generalized
or
disseminated
GA is an uncommon variant displaying some clinical features that differentiate it from the localized form, including later age of onset, inadequate response to treatment, and less tendency to spontaneous resolution. The treatment modalities used for localized GA (topical or intralesional steroids, freezing with liquid nitrogen, or surgical excision) cannot be successfully applied to the large numbers of lesions seen in GA’s generalized form. Systemic treatments have included dapsone, chlorambucil, isotretinoin, systemic steroids, cyclosporine, salicylates, chloroquine, and PUVA. These treatments have potentially serious side effects in the long term and have not demonstrated consistent results. Literature overuse of pentoxifylline in the treatment of GA is limited. Here we report three prospective cases of generalized GA showing resolution with oral pentoxifylline.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
1,969
37
-
Topical 5-fluorouracil for Basal Cell Carcinoma
Anil Balkrishna Bhokare
January-June 2022, 8(1):29-31
DOI
:10.4103/ijdd.ijdd_20_20
Basal cell carcinoma is a malignant epithelial tumor arising only in skin, from the basal layer of the epidermis or of the pilosebaceous adnexa. Diagnosis often depends on skin examination, confirmed by tissue biopsy. Treatment is typically by surgical removal. This can be by simple excision if the cancer is small; otherwise Mohs surgery is generally recommended. Other options may include topical chemotherapy, laser therapy, or the use of imiquimod. In this study, we conclude topical 5-fluorouracil is a highly effective and well-tolerated treatment option for superficial basal cell carcinomas.
[ABSTRACT]
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
1,722
62
-
LETTERS TO THE EDITOR
Tetracyclines and niacinamide to the rescue in a case of dermatitis herpetiformis
Surender Singh, Siddhi Chikhalkar, Vidya Kharkar, Prateek Oswal
January-June 2022, 8(1):43-45
DOI
:10.4103/ijdd.ijdd_32_21
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
1,122
34
-
Acute generalized exanthematous pustulosis: A case highlighting the uncommon side effect of a common anti-Covid drug doxycycline in the era of Covid-19 pandemic
Ipsita Debata, Debasmita Behera, Chinmoy Raj, Abhishek C Lachure
January-June 2022, 8(1):46-48
DOI
:10.4103/ijdd.ijdd_16_21
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
968
32
-
Gratifying results of apremilast in unstable erythrodermic psoriasis
Meghana Chandrashekhar Rane, Vidya Kharkar
January-June 2022, 8(1):40-42
DOI
:10.4103/ijdd.ijdd_27_21
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
942
33
-
Correlation between percentage of atypical lymphocytes in peripheral smear and disease severity based on internal organ involvement in drug reaction with eosinophilia and systemic symptoms
Reshma J Neerackal, Dhanya Mohan, Anand G Archana, Biju George, Aparna Govindan, Chettithodi Sivasankaran Bindu, Sarita Sasidharanpillai
January-June 2022, 8(1):52-54
DOI
:10.4103/ijdd.ijdd_12_21
[FULL TEXT]
[PDF]
[Mobile Full text]
[EPub]
941
32
-
Topical steroid induced central serous chorioretinopathy- a rare side-effect
Paras Choudhary, Prachi Vinayak Gole, Bhushan Amol Darkase, Balasaheb Vishwas Malkar
January-June 2022, 8(1):49-51
DOI
:10.4103/ijdd.ijdd_40_20
[FULL TEXT]
[PDF]
887
34
-
Angiolymphoid hyperplasia: Excellent response to polidocanol sclerotherapy
Vikrant M Jadhav, Anil S Gugle, Nitin G Barde
January-June 2022, 8(1):38-39
DOI
:10.4103/ijdd.ijdd_51_19
[FULL TEXT]
[PDF]
806
31
-
Sitemap
|
What's New
|
Feedback
|
Disclaimer
|
Privacy Notice
© Indian Journal of Drugs in Dermatology | Published by Wolters Kluwer -
Medknow
Online since 26
th
November, 2015